[PDF][PDF] CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer

E Chipumuro, E Marco, CL Christensen, N Kwiatkowski… - Cell, 2014 - cell.com
E Chipumuro, E Marco, CL Christensen, N Kwiatkowski, T Zhang, CM Hatheway…
Cell, 2014cell.com
The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through
amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit
MYC function as potential cancer therapy. Using a covalent inhibitor of cyclin-dependent
kinase 7 (CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, we
demonstrate downregulation of the oncoprotein with consequent massive suppression of
MYCN-driven global transcriptional amplification. This response translated to significant …
Summary
The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit MYC function as potential cancer therapy. Using a covalent inhibitor of cyclin-dependent kinase 7 (CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, we demonstrate downregulation of the oncoprotein with consequent massive suppression of MYCN-driven global transcriptional amplification. This response translated to significant tumor regression in a mouse model of high-risk neuroblastoma, without the introduction of systemic toxicity. The striking treatment selectivity of MYCN-overexpressing cells correlated with preferential downregulation of super-enhancer-associated genes, including MYCN and other known oncogenic drivers in neuroblastoma. These results indicate that CDK7 inhibition, by selectively targeting the mechanisms that promote global transcriptional amplification in tumor cells, may be useful therapy for cancers that are driven by MYC family oncoproteins.
cell.com